Shiao-Wen David Hsu, MD

Assistant Professor of Medicine
William Dalton Family Assistant Professor of Medical Oncology, in the School of Medicine
Member of the Duke Cancer Institute
Campus mail Dept of Medicine, Box 3233, Durham, NC 27710
Phone (919) 681-3480
Email address shiaowen.hsu@duke.edu

Education and Training

  • Fellow in Hematology-Oncology, Medicine, Duke University, 2004 - 2007
  • Medical Resident, Medicine, University of Texas at Dallas, 2001 - 2004
  • M.D., University of North Carolina at Chapel Hill, 2001

Publications

Strickler, J. H., S. McCall, A. B. Nixon, J. C. Brady, H. Pang, C. Rushing, A. Cohn, et al. “Phase i study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer.” Investigational New Drugs 32, no. 2 (January 1, 2014): 330–39. https://doi.org/10.1007/s10637-013-0042-9.

Full Text

Rangwala, F., J. C. Bendell, M. F. Kozloff, C. C. Arrowood, A. Dellinger, J. Meadows, S. Tourt-Uhlig, et al. “Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors.” Investigational New Drugs 32, no. 4 (January 1, 2014): 700–709. https://doi.org/10.1007/s10637-014-0089-2.

Full Text

Morse, M. A., D. Niedzwiecki, J. L. Marshall, C. Garrett, D. Z. Chang, M. Aklilu, T. S. Crocenzi, et al. “A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer.” Annals of Surgery 258, no. 6 (December 1, 2013): 879–86. https://doi.org/10.1097/SLA.0b013e318292919e.

Full Text

Morse, Michael A., Arvind Chaudhry, Elizabeth S. Gabitzsch, Amy C. Hobeika, Takuya Osada, Timothy M. Clay, Andrea Amalfitano, et al. “Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients..” Cancer Immunol Immunother 62, no. 8 (August 2013): 1293–1301. https://doi.org/10.1007/s00262-013-1400-3.

PMID
23624851
Full Text

Zani, Sabino, Katia Papalezova, Sandra Stinnett, Douglas Tyler, David Hsu, and Dan G. Blazer. “Modest advances in survival for patients with colorectal-associated peritoneal carcinomatosis in the era of modern chemotherapy..” J Surg Oncol 107, no. 4 (March 2013): 307–11. https://doi.org/10.1002/jso.23222.

PMID
22811275
Full Text

Mettu, N. B., H. Hurwitz, and D. S. Hsu. “Use of molecular biomarkers to inform adjuvant therapy for colon cancer.” Oncology (United States) 27, no. 8 (January 1, 2013).

Scholars@Duke

Uronis, Hope E., Johanna C. Bendell, Ivy Altomare, Gerard C. Blobe, S David Hsu, Michael A. Morse, Herbert Pang, et al. “A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas..” Oncologist 18, no. 3 (2013): 271–72. https://doi.org/10.1634/theoncologist.2012-0404.

PMID
23485624
Full Text

Zani, S., K. Papalezova, S. Stinnett, D. Tyler, D. Hsu, and D. G. B. III. “Modest advances in survival for patients with colorectal-associated peritoneal carcinomatosis in the era of modern chemotherapy.” Journal of Surgical Oncology 107, no. 4 (2013): 307–11. https://doi.org/10.1002/jso.23222.

Full Text

Morse, M. A., A. Chaudhry, E. S. Gabitzsch, A. C. Hobeika, T. Osada, T. M. Clay, A. Amalfitano, et al. “Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients.” Cancer Immunology, Immunotherapy 62, no. 8 (2013): 1293–1301. https://doi.org/10.1007/s00262-013-1400-3.

Full Text

Kim, Mickey K., Takuya Osada, William T. Barry, Xiao Yi Yang, Jennifer A. Freedman, Katherine A. Tsamis, Michael Datto, et al. “Characterization of an oxaliplatin sensitivity predictor in a preclinical murine model of colorectal cancer..” Mol Cancer Ther 11, no. 7 (July 2012): 1500–1509. https://doi.org/10.1158/1535-7163.MCT-11-0937.

PMID
22351745
Full Text

Pages